Recent publications



  1. Clin Cancer Res Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft Tissue Sarcomas: Clinical Outcomes and Biological Correlates
  2. Cancer Immunol Immunother Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment
  3. Lab Invest. 2023 Profiling of Natural Killer Interactions With Cancer Cells Using Mass Cytometry.
  4. Cancer Cell. 2022. Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.
  5. Proc Natl Acad Sci U S A. 2022. Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia
  6. Immunotherapy. 2022. Multiple high-grade and rare immune-related adverse events in a colon cancer patient with genomic and cytokine profiling
  7. STAR Protoc. 2022. Simplified mass cytometry protocol for in-plate staining, barcoding, and cryopreservation of human PBMC samples in clinical trials
  8. J Clin Invest. 2022. Expansion, persistence, and efficacy of donor memory-like NK cells infused for post transplant relapse
  9. J Immunother Cancer. 2022. Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors
  10. STAR Protocols. 2022. Mass cytometry staining for human bone marrow clinical samples
  11. Blood Adv. 2021. GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized double blinded phase 2 trial
  12. J Immunother Cancer. 2021. Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial
  13. J Immunother Cancer. 2021. Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival
  14. Nat Commun. 2021. Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer
  15. Blood Adv. 2021. Coevolving JAK2V617F+ relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index case
  16. J Immunother Cancer. 2021. Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)
  17. Cancer Immunol Immunother. 2021. Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors
  18. Blood. 2021. Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation
  19. Cancer Cell. 2021. A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation
  20. Clin Cancer Res. 2021. A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer
  21. Cancer Immunol Immunother. 2021. Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors
  22. Clin Cancer Res. 2021. Randomized phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for recurrent glioblastoma patients
  23. J Immunother Cancer. 2020. Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC
  24. Int J Radiat Oncol Biol Phys. 2020. A randomized phase II study of pembrolizumab with or without radiation in patients with recurrent or metastatic adenoid cystic carcinoma